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Abstract
Background: Chronic HIV infection is associated with low-level inflammation and increased risk of chronic diseases
and mortality. The objective was to assess the effects of moderate intensity exercise on metabolic and inflammatory
markers in HIV-infected treated persons.
Methods: This was a pilot study enrolling cART-treated, sedentary persons with metabolic complications in a 12-week
protocol, consisting of three sessions per week of 60 min brisk walking with (strength-walk group) or without (walk
group) 30 min circuit-training. Assessments at baseline and week 12 (W12) included body morphometrics and total
body dual-energy X-ray absorptiometry; lipid and glucose blood profile; plasma level of high sensitivity C-reactive
protein (hsCRP), interleukin-6 (IL-6), D-dimer, interleukin-18 (IL-18), soluble CD14, and CD38 and HLA-DR expression on
CD4+ and CD8+ T-cells.
Results: Forty-nine patients were included and 35 (71%) completed the program: 21 in the walk and 14 in the
strength-walk group. At W12, significant improvements were observed of body mass index, waist and hip
circumference, and total cholesterol both overall and in the walk group, and of LDL cholesterol in both training
groups. In the whole group, significant reductions were observed in hsCRP, IL-6, D-dimer, IL-18, and of CD8
+/CD38+/HLA-DR+ cell frequencies. HsCRP and CD8+/CD38+/HLA-DR+ frequency decreased significantly in
both training groups when examined separately whereas IL-6 and D-dimer in the walk group only.
Conclusions: Brisk walking, with or without strength exercise, could improve lipid profile and inflammatory
markers in chronic HIV infection.
Trial registration: ACTRN12615001258549, registered 17 November 2015, “retrospectively registered” Web
address of trial: http://www.ANZCTR.org.au/ACTRN12615001258549.aspx
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Background
Physical activity has been shown to improve the health
and quality of life among people with HIV infection [1].
In the general population, it delays all-cause mortality and
reduces the risk of cardiovascular disease (CVD), stroke,
type-2 diabetes and some types of cancer [2]. These dis-
eases are associated with chronic inflammation, which is
characterized by activation of inflammatory signaling path-
ways with abnormal production of cytokines and other
mediators [3]. Observational studies of large population
cohorts have consistently shown an association between
physical inactivity and low-grade systemic inflammation
and interventional studies a reduction of inflammatory
markers following exercise [4].
Chronic inflammation is also a predominant feature of
treated human immunodeficiency virus (HIV) infection
[5, 6]. Compared to age-matched HIV-negative subjects,
persons with chronic HIV infection are at higher risk to
develop non-acquired immune deficiency syndrome (AIDS)
related chronic diseases [7], and several studies have shown
an association between chronic inflammation and higher
cardiovascular risk and overall mortality [8, 9].
We hypothesized that, like in the general population,
physical exercise could decrease inflammation in HIV
infection. We designed a pilot study of moderate physical
activity [2], consisting of brisk walking, with or without
strength exercise, with the objective to assess its effects
on metabolic parameters and inflammatory markers in
treated HIV-infected persons. In addition, we assessed
measures of fitness outcome and evaluated potential
differences in all the measures between type of exercise,
i.e., resistance only versus resistance plus strength train-
ing, and gender. More in general, we also aimed to assess
feasibility of the proposed physical activity approach that
could help in the design of larger controlled clinical trials.
Methods
Study design
This was a 12-week pilot study, which enrolled sedentary
HIV-infected patients receiving combination antiretroviral
treatment (cART). Inclusion criteria were: age ≥18 years;
cART for ≥6 months; sedentary lifestyle, defined as phys-
ical activity for <2 days per week for <20 min per session;
either objective evidence of lipodystrophy, as established
by the visiting physician (PC, SB) [10], or of at least one of
the Adult Treatment Panel III definition criteria of the
metabolic syndrome [11]. Exclusion criteria included any
disease requiring hospitalization in the 6 weeks before en-
rollment; medical conditions contraindicating exercise as
established by a sport medicine specialist; inability to walk
at brisk pace; current substance or alcohol abuse. The
study protocol was approved by San Raffaele Hospital
Ethical Committee (approved on 03/03/2011, prot. N. 142/
11) in accordance with current national and international
laws and regulations governing the use of human subjects
(Declaration of Helsinki II). Written informed consent was
obtained from all study participants. This trial was regis-
tered retrospectively at Australian New Zealand Clinical
Trials Registry (ACTRN12615001258549). This study has
not been registered as a clinical trial before its initiation be-
cause, at the time it started in March 2011, it was consid-
ered exempt from registration based on the Food and
Drug Administration Amendments Act (FDAAA) 801
requirements. According to those requirements, “Trials
that do not include drugs, biologics, or devices (such as
behavioral interventions) … are generally excluded from the
registration (and results submission) requirements of FDAAA
801” (https://clinicaltrials.gov/ct2/manage-recs/fdaaa).
Participant screening and protocol
Participants were recruited from the outpatient Clinic of
the Department of Infectious Diseases of San Raffaele
Hospital, upon invitation by the caring physician or
through advertisement with posters in the Hospital and
online through patients’ associations websites. Potential
participants were screened for eligibility by an infectious
diseases specialist (SB, PC) and a sport medicine special-
ist (GM), after performing electrocardiogram at rest and
during sub-maximal cycle ergometer test. Patients who
met the above inclusion criteria and with no contraindi-
cations to exercise were offered to either join the ‘walk’
group, consisting of brisk walking only, or the ‘strength-
walk’ group, where each walking session was preceded
by a strength exercise session.
Participants trained three times a week for 12 weeks.
The walking sessions were performed outdoor on mea-
sured tracks in green areas in Milan in four groups of
10–15 subjects. To favour adherence to outdoor train-
ing, sessions were planned in the periods March-July,
2011 and 2012 (recruitment started on March 4th 2011;
last follow up August 15th, 2012). Each walking session
consisted of 60 min at an intensity of 65–75% of maximal
HR (HRmax) [12]. Each participant was equipped with a
personal HR monitor (Polar FT4, Polar Electro 2011,
Kempele, Finland) with an acoustic warning if HR was
below or exceeded the predetermined range, which was
maintained throughout the study. Mean HR (HRmean) was
recorded during each session, with values captured every
5 s. Strength exercise was carried out in a gym by circuit
training, including crunch, lat machine, chest press, leg
press, leg extension, sitting calf. Each exercise was re-
peated 12 times for three sets at 65% of 1-Repetition Max-
imum (1RM) Test. The walking session was performed
outdoor following the resistance training. Professional
coaches (MB, GP, ALT) supervised both strength and
aerobic training sessions providing technical instruction,
supervision and encouragement. Participants received
generic dietary advice by the sport medicine specialist
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involved in the program (GM), consisting of a total
food intake of ≤ 2000 Kcal/day (corresponding to ≤ 8374
Kj), including 50–60% carbohydrates, 15–30% proteins
and 20–30% fat. Study variables were assessed at base-
line (BL) and at the end (W12) of the program. All the
demographic and clinical variables were recorded at BL
visit through patient interview and access to clinical
records.
Physical fitness evaluation
6 min walking test (6MWT)
Participants were instructed to walk as fast as possible
for six minutes on a 400-m outdoor athletic track [13].
HRmean was recorded during the test, blood lactate con-
centration was assessed before and 3 min after 6MWT
(Lactate ProTM, Arkray KdK, Japan), and the Rating of
Perceived Exertion (RPE) [14] before and at the end of
6MWT.
Strength measurements
1-RM test assessed the maximal load lifted in one repeti-
tion for all the strength exercises performed on weight
machines, and the 30-s crunch test the number of
crunches performed in 30 s.
Body composition
Anthropometric variables included weight, body mass
index (BMI), waist, hip, and thigh circumference on domin-
ant side. Total and % fat mass, lean mass and body mineral
content (BMC) at arms, limbs, trunk and as total body was
measured by dual-energy X-ray absorptiometry (DEXA)
(Lunar Prodigy, version 8.8, GE Medical Systems, Madison,
WI). Superficial and visceral fat was measured by ultrason-
ography at the periumbilical skin-point [15].
Laboratory analysis
Metabolic parameters
Blood examination for metabolic parameters included fast-
ing total, high-density lipoprotein (HDL) and low-density
lipoprotein (LDL) cholesterol, triglycerides, glucose, insu-
lin, glycated haemoglobin (HbA1c). Based on these values,
the Homeostatic Model Assessment (HOMA)-I index was
also calculated.
Other blood examinations
Additional examinations included complete blood count
and standard biochemical exams; cluster of differenti-
ation 4 (CD4+) and cluster of differentiation 8 (CD8+)
T-cell counts, HIV-1-RNA plasma level (Abbott RealTime
HIV-1 assay). The Veterans Aging Cohort Study Risk
(VACS) index was also calculated [16].
Inflammatory markers
Soluble markers
Soluble biomarkers were measured in cryopreserved
plasma samples, drawn at BL and W12, by commercially
available enzyme-linked immunosorbent assays according
to manufacturers’ recommendation. These included high-
sensitivity C-reactive protein (hsCRP, Catalog Number
DCRP00), interleukin-6 (IL-6, Catalog Number D6050)
and soluble CD14 (sCD14, Catalog Number DC140)
(R&D Systems, Minneapolis, MN), D-dimer (Asserachrom,
Diagnostica Stago, Asnieres-Sur-Seine, France), interleukin-
18 (IL-18) (Medical and Biological Laboratories, Nagoya,
Japan).
Flow cytometry for cell-activation markers
T-cell activation was measured on cryopreserved periph-
eral blood mononuclear cells isolated by Ficoll-Paque
gradient from EDTA-anticoagulated whole blood. After
thawing and PBS-washing, 3 × 105 cells were stained using
phycoerythrin (PE)-conjugated anti-HLA-DR, PE-cyanin
red 5.1-conjugated anti-CD38, Alexa Fluor 647-conjugated
anti-CD3, fluorescein isothiocyanate-conjugated anti-CD4
or anti-CD8 (BD-Biosciences, San Diego, CA). CD38+ and
HLA-DR+ cells were gated from the CD3+/CD4+ or
CD3+/CD8+ cells on a 2-dimensional dot plot. Ana-
lyses were performed by FACSCalibur with CellQuest
software (BD-Biosciences) and results reported as per-
centages of CD3+/CD4+ and CD3+/CD8+ T-cells ex-
pressing both HLA-DR and CD38.
For both soluble and inflammatory markers, samples
were analysed in batch at the end of the study and blindly
with respect to group assignment.
Retention in study and adherence
Participants were withdrawn from the study if they
missed the exercise sessions for ≥ 2 consecutive weeks
(corresponding to 6 sessions). Adherence to the program
was defined as the proportion of sessions attended dur-
ing the 12-week training period and it was calculated
only among the participants who completed the study.
Statistical analysis
Quantitative variables were expressed as median and 25–
75% interquartiles (Q1-Q3). The Kolmogorov-Smirnov
test was performed to test normality of distribution. Since
many of the tested variables were not normally distrib-
uted, nonparametric tests were used. Changes between
BL and W12 were assessed by Wilcoxon matched-pairs
signed rank test, BL values and % change differences
between groups by Mann–Whitney test, and correlations
of continuous variables by the Spearman’s test. Statistical
analysis was performed using Graph Pad Prism Software,
version 6.0 for Macintosh (Graph Pad Software, San
Diego, CA). Level of significance was set at 0.05.
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Results
Patient disposition and baseline characteristics
Fifty-nine patients underwent a screening visit and 49
were eligible: 29 joined the walk group and 20 the
strength-walk group. Fourteen subjects (29%) dropped
out and were not included in the analyses (Fig. 1).
Thirty-five subjects were evaluated at W12, including
21 in the walk group and 14 in the strength-walk
group.
Of 59 screened patients, 49 were eligible for the study.
Non eligibility was due to ambulatory or orthopedic prob-
lems, doing exercise > 2 times a week (2 subjects each),
not on ART, cardiovascular disease, chemotherapy for
lymphoma, renal failure, liver cirrhosis with esophageal
varices, severe psychiatric problems (1 subject each).
Thirty-five patients completed the study while 14
dropped-out after a median of 5 weeks (range, 2–7).
Reasons for drop-out were inability to handle family or
work commitments (walk group, n = 5; strength-walk
group, n = 5), medical problems unrelated to the study
(walk group, n = 2; strength-walk group, n = 1), exercise
perceived as “too hard” (walk group, n = 1).
BL patients’ characteristics are shown in Table 1. Ex-
cept for gender, there was no difference between the two
training subgroups in demographic and clinical variables.
Because all women trained in the walking group, post-
exercise changes were also analysed according to gender
within the walk group.
Physical fitness
Performance during the training sessions
Median overall adherence to the sessions was 67% (drop-
out subjects were not considered). Participants walked a
median distance of 122 km in 12 weeks (5040 m each ses-
sion) at a median exertion of 66% HRmax (Table 2). Partici-
pants in the strength-walk group walked longer distances
than those in the walk group, both in each session and as
a total. No different performances were observed between
women and men within the walk group (see Additional
file 1: Table S1).
6MWT
At W12 6MWT, participants walked for a significantly
longer distance compared to BL both in the overall sample
and in the two subgroups, in parallel with significant in-
creases of HRmean, HRmax and delta lactate (Table 3). The
distance improvement from BL did not differ between
subgroups and between women and men (Additional
file 2: Table S2). Overall, better distance improvement
correlated with higher adherence (r = 0.580; p = 0.0003)
and longer walked distance (r = 0.555; p = 0.0005) during
the 12 weeks of training (Spearman’s correlation.
1-RM and 30-s crunch tests
In the strength-walk group, training was followed by
significant improvement of performance for all strength
exercises (Additional file 3: Table S3).
Fig. 1 Patient flow diagram
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Body composition
Significant reductions were observed of weight, BMI and
waist and hip circumference in the whole group. Weight,
BMI reduction and waist circumference reductions were
maintained in the walk group only (Table 4). However,
changes of these parameters from BL did not differ be-
tween the two training groups.
No significant changes were observed by DEXA of
fat and lean mass or BMC, or of superficial, visceral or
total fat by ultrasonography (Table 4, Additional file 4:
Table S4). Within the walk group, none of the above
parameters was significantly reduced when women
and men were analysed separately (Additional file 5:
Table S5).
Table 1 Baseline characteristics of the 35 participants who completed the study
All (n = 35) Walk (n = 21) Strength-Walk (n = 14)
Demographic and general characteristics
Male gendera 26 (74%) 12 (57%)a 14 (100%)a
Age (years, median, Q1-Q3) 48 (44–54) 48 (43–54) 49 (44–54)
Caucasian race 35 (100%) 21 (100%) 14 (100%)
BMI (Kg/m2) 25.6 (22.2-27.2) 25.3 (21.6-27.5) 25.8 (24.1-26.9)
Risk Group
Ex-intravenous drug users 8 (23%) 7 (33%) 1 (7%)
Men-having-sex-with-men 21 (57%) 7 (33%) 13 (93%)
Heterosexual infection 6 (17%) 6 (29%) 0
Vertical infection 1 (3%) 1 (5%) 0
HIV infection variables
Previous AIDS-defining events 9 (25%) 7 (33%) 2 (14%)
Nadir CD4+ T-cells/μL (median, Q1-Q3) 94 (37–197) 80 (34–140) 188 (77–258)
Current CD4+ T-cells/μL (median, Q1-Q3) 577 (406–726) 485 (374–686) 624 (527–740)
VL < 40 c/mL 34 (97%) 21 (100%) 13 (93%)
Hepatitis C virus coinfection 4 (11%) 4 (19%) 0
VACS Index 12 (5–19) 16 (6–24) 9 (0–12)
Smoking and Treatments
Smokers 8 (23%) 6 (29%) 2 (14%)
2NRTI + Protease inhibitor 14 (40%) 7 (33%) 7 (50%)
2NRTI + NNRTI 11 (31%) 7 (33%) 4 (29%)
Other ART regimens 10 (28%) 7 (33%) 3 (21%)
Beta blockersb 6 (17%) 5 (24%) 1 (7%)
Other anti-hypertensive drugsb 5 (14%) 2 (10%) 3 (21%)
Statinsb 10 (29%) 4 (19%) 6 (42%)
Fibratesb 2 (6%) 0 2 (14%)
Inclusion Criteria
Lipodystrophy 35 (100%) 21 (100%) 14 (100%)
≥ 1 metabolic syndrome criterion 32 (91%) 19 (90%) 13 (93%)
Blood triglycerides ≥150 mg/dL 14 (40%) 8 (38%) 6 (42%)
Blood HDL-C ≤40 (m) or ≤50 (w) mg/dL 12 (34%) 9 (43%) 3 (21%)
Blood glucose ≥110 mg/dL 1 (3%) 0 1 (7%)
Waist ≥102 (m) or ≥88 (w) cm 10 (28%) 8 (38%) 2 (14%)
SBP ≥150 or DBP ≥85 mmHg 12 (34%) 7 (33%) 5 (36%)
Values are expressed as number of patients (%) where no otherwise indicated
aWalk vs. strength-walk, p = 0.005
bChronic treatment, with no changes during the training period or the 6 weeks before training
VACS Veterans Ageing Cohort Study, NRTI nucleoside reverse transcriptase inhibitors, NNRTI non-nucleoside reverse transcriptase inhibitors, m men, w women,
SBP systolic blood pressure, DBP, diastolic blood pressure
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Laboratory examinations
At W12, significant reductions were observed of total
and LDL cholesterol values in the whole sample. Both
were also decreased in the walk group, and LDL choles-
terol in the strength-walk group (Table 5). Changes from
BL did not differ between groups. Within the walk group,
cholesterol improvement was observed in men but not in
women (see Additional file 5: Table S5).
Among 25 statin-untreated patients, total, LDL, and
also HDL cholesterol improved significantly both in the
overall sample and in the walk group, and both total and
LDL cholesterol were decreased in the strength-walk
group (Additional file 6: Table S6).
No significant changes were observed of the other la-
boratory variables (Table 5, Additional file 4: Table S4).
Inflammatory markers
Soluble and cell inflammatory markers were examined
in a total of 25 and 16 patients, respectively.
Overall, significant reductions were observed of hsCRP,
IL-6, D-dimer and IL-18, but not of sCD14, and of
CD8+/CD38+/HLA-DR+, but not CD4+/CD38+/HLA-
DR+ cell frequencies (Fig. 2). HsCRP and CD8+/CD38+/
HLA-DR+ frequency decreased significantly in both training
groups, and IL-6 and D-dimer in the walk group only. Sub-
jects with D-dimer concentration above the reference value
of 250 ng/mL were 15 of 25 (60%) at BL and 8 of 25 (32%)
after exercise (p= 0.047, Chi-square test). Subjects with
hsCRP above 2 mg/L, i.e., the value considered to confer
higher risk for cardiovascular disease in the general popula-
tion, were 13 of 25 (52%) at BL and 8 of 25 (32%) after
12 week of exercise (p= n.s.).
Changes from BL did not differ between training
groups. Within the walk group, significant reductions of
IL-6 and D-dimer were observed in women and of hsCRP
in men (Additional file 7: Table S7).
Twenty-five patients were evaluated for soluble markers
(walk, n = 15; strength-walk, n = 10), and 16 for cell
markers (walk, n = 10; strength-walk, n = 6).
For each group, first and second columns represent
values at BL and W12, respectively. Horizontal bars in-
dicate median and Q1-Q3 values (*P < 0.05; **P < 0.01;
****P < 0.0001).
HsCRP, high sensitivity C-reactive protein; IL-6,
interleukin-6; IL-8, interleukin-18; sCD14, soluble CD14.
We neither observed significant intercorrelations be-
tween changes of inflammatory markers, nor between in-
flammatory markers and other variables changes.
Table 2 Participants performance during the 12 weeks of training
All Walk Strength-walk
Adherence (%) 67 (58–75) 61 (56–72) 69 (63–79)
Total walked distance (Km) 122 (84–146) 105c (73–139) 136c (121–155)
Total energy expenditure (KJ/Kg)a 298.18 (205.31-356.84) 248.84 (173.00-329.84) 344.67 (306.65-392.82)
Walked distance/session (m) 5040 (4380–5500) 4740d (3535–5390) 5330d (4980–5700)
Energy expenditure per session (KJ/Kg)a 12.32 (10.10-14.28) 11.23 (8.01-13.77) 13.51 (12.09-15.25)
HRmean (% of HRmax)
b 66 (62–75) 66 (58–73) 70 (63–86)
Values as expressed as median (Q1-Q3). W12 values were compared to BL values by the Wilcoxon matched-pairs signed rank test
aCalculation was based on the U shape relationship between walking metabolic cost and speed [43]
bThe median HRmean value was calculated for each participant through all her/his walking sessions, to derive the median HRmean value of all participants
cWalk vs. strength-walk group, p = 0.029 (Mann–Whitney test)
dWalk vs. strength-walk group, p = 0.027 (Mann–Whitney test)
No significant differences were observed between the two training groups for adherence, total and per session energy expenditure, and HRmean
HR heart rate
Table 3 Physical fitness values at baseline (BL) and week-12 (W12)
All Walk Strength-Walk
BL W12 p BL W12 p BL W12 p
6 min Walking Test
Distance (m) 642 (605–715) 730 (695–830) <0.0001 620 (590–701) 700 (660–807) <0.0001 684 (634–724) 792 (714–850) <0.0001
HRmean (bpm) 119 (107–132) 137 (116–152) <0.0001 118 (107–135) 128 (116–154) 0.0003 121 (107–133) 138 (116–153) 0.004
HRmean (%HRmax) 69 (63–75) 73 (63–75) <0.0001 69 (59–75) 71 (63–83) <0.0001 69 (63–75) 75 (68–79) 0.0005
Δ[La−] (mmol/L) 0.9 (0.2-2.2) 1.9 (0.5-4.1) n.s. 0.8 (0.0-2.3) 1.2 (0.5-2.6) n.s. 1.0 (0.6-2.1) 3.3 (0.7-4.5) n.s.
Δ RPE 1.0 (0–1) 0.5 (0–2) n.s. 0.5 (0.0-2.0) 0.5 (0.0-0.2) n.s. 1.0 (0.0-1.0) 0.5 (0.2-2.0) n.s.
Values are expressed as median (Q1-Q3). W12 values were compared to BL values by the Wilcoxon matched-pairs signed rank test
HR heart rate, Δ[La−] difference in lactate blood concentration between before and after 6MWT, Δ RPE difference in Rate of Perceived Exertion between before
and after 6MWT
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Discussion
This pilot study explored the efficacy of a 3-day per week,
12-week program of brisk walking, with or without
strength exercise, on metabolic and inflammatory markers
in sedentary cART-treated persons with metabolic compli-
cations. We observed, in parallel with improvement of
physical fitness and of some morphometric measures,
substantial improvements of cholesterol profiles and in-
flammatory markers. Many of the changes were observed
in both training groups and, within the walk group, most
changes did not differ substantially between women and
men.
From a clinical standpoint, a remarkable observation
was the general reduction of total cholesterol, the reduc-
tion of LDL cholesterol in both training groups, and the
increase of HDL among statin-untreated participants.
Total, HDL and LDL cholesterol are each independent
strong predictors of CVD in the general population and el-
evated LDL is the primary target for cholesterol-lowering
therapy [17, 18]. While high intensity aerobic exercise is
followed by favorable cholesterol alterations, the influence
of moderate intensity aerobic and of resistance training is
not clearly evidence-supported [19]. Only a few studies
have examined the effects of exercise on blood lipids in
Fig. 2 Soluble and cell inflammatory markers at baseline (BL) and week-12 (W12)
Table 5 Laboratory values at baseline (BL) and week-12 (W12)
All Walk Strength-Walk
BL W12 p BL W12 p BL W12 p
Total Cholesterol (mg/dL) 196 (163–236) 186 (162–215) 0.018 190 (157–229) 180 (151–214) 0.042 217 (174–237) 191 (165–232) n.s.
HDL-Cholesterol (mg/dL) 46 (34–54) 47 (36–56) n.s. 45 (34–55) 47 (35–56) n.s. 46 (33–56) 45 (35–59) n.s.
LDL-Cholesterol (mg/dL) 124 (106–155) 108 (93–139) 0.004 116 (96–148) 103 (89–138) 0.033 147 (120–164) 121 (106–144) 0.031
Triglycerides (mg/dL) 143 (111–201) 131 (93–200) n.s. 142 (101–222) 112 (80–205) n.s. 137 (107–210) 165 (121–283) n.s.
Glucose (mg/dL) 85 (78–92) 82 (79–93) n.s. 85 (74–92) 81 (79–92) n.s. 86 (80–93) 82 (78–93) n.s.
Insulin (mg/dL) 11.8 (7.9-16.5) 13.0 (8.0-16.9) n.s. 10.2 (5.8-17.0) 13.8 (6.6-17.2) n.s. 13.1 (9.9-15.2) 10.3 (8.6-18.8) n.s.
HOMA-Index 2.8 (1.6-3.4) 2.7 (1.7-4.1) n.s. 2.3 (0.9-3.7) 2.8 (1.2-4.1) n.s. 3.0 (2.1-3.3) 2.3 (1.8-5.0) n.s.
HbA1c (%) 5.3 (5.1-5.8) 5.5 (5.3-5.6) n.s. 5.2 (5.0-5.7) 5.3 (5.1-5.6) n.s. 5.5 (5.3-5.9) 5.5 (5.5-6.0) n.s.
CD4+ T-cells/μL 577 (407–726) 559 (445–715) n.s. 485 (365–686) 557 (365–684) n.s. 642 (527–740) 587 (481–796) n.s.
CD8+ T-cells/μL 821 (652–914) 747 (566–975) n.s. 766 (581–872) 743 (632–950) n.s. 916 (783–1349) 747 (561–1090) n.s.
VACS index 12 (5–19) 12 (0–21) n.s. 16 (6–24) 17 (3–22) n.s. 9 (0–12) 10 (0–18) n.s.
Values are expressed as median (Q1-Q3). W12 values were compared to BL values by the Wilcoxon matched-pairs signed rank test
HOMA Homeostasis Model Assessment, VACS Veterans Ageing Cohort Study
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HIV infection, with inconsistent outcomes, likely resulting
from large variability of populations and exercise interven-
tions [20–22]. Our findings indicate that moderate exercise
may reduce blood cholesterol in HIV infection, supporting
exercise interventions including prior to use of cholesterol-
lowering drugs [17].
In contrast, we observed no improvement in glucose
or insulin level. Functional tests in the general population
and HIV-positive patients showed that exercise improves
insulin resistance, but often without changes of glucose,
insulin or glycate haemoglobin level [22]. Thus, the exer-
cise program followed in this study either had no effect on
glucose metabolism or blood static markers did not reflect
a possible exercise-induced benefit on glucose control.
Because the HRmean during the training session was
set in the so-called fat-burning zone, the observed weight
reductions were not unexpected. BMI and waist circum-
ference reductions were less marked in the strength-walk
group participants, although they walked longer distances
than those in the walking group, likely resulting from in-
crease of muscle mass. Indeed, there was a median in-
crease of lean mass of 1.35 Kg by DEXA examination in
the strength-walk group, in contrast from what observed
in the walk group, in which no substantial change of lean
mass was observed. However, body changes were in gen-
eral mild, there were no modification of the waist-hip ratio
and no significant change in body composition by DEXA
or ultrasound examination. Since we prescribed no spe-
cific diet, the limited effect of exercise on body fat might
reflect an unbalanced caloric intake following exercise. It
is also possible that 12 weeks of brisk walking was not suf-
ficient to reduce visceral fat, similar to what observed in
obese subjects with type-2 diabetes or dyslipidaemia, likely
resulting from a reduced capacity of fat oxidation [23, 24].
cART-controlled chronic HIV infection is associated
with increased inflammation and coagulation [5, 6, 25],
and higher plasma levels of hsCRP, IL-6 and D-dimer
strongly predicted higher overall mortality and cardio-
vascular events [8, 9]. Beyond cART, a number of inter-
ventions are in use, e.g., statins, or proposed, to treat
inflammation [26]. However, the anti-inflammatory effect
of exercise in HIV infection has been rarely addressed in
clinical studies. Reductions of hsCRP, IL-6, TNF-α and
IL-18, a cytokine released by adipocytes and other cell
types, were observed in a 16-week study of aerobic or
resistance training performed at variable intensity [22],
but no of IL-6 after 6 weeks of aerobic plus resistance
moderate intensity exercise [27].
In HIV-negative subjects, a number of longitudinal
studies have demonstrated exercise-induced changes of
plasma inflammatory markers. These have largely focused
on hsCRP and IL-6, showing more marked reductions in
subjects with higher baseline levels, but no or low effect in
healthy persons [4, 28]. Scattered studies have shown
reductions of plasma IL-18 in old healthy and diabetic
subjects [29, 30]. No information is available on the effect
of exercise on D-dimer levels, although levels of other co-
agulation markers may improve following exercise [31].
Thus, our findings extend previous observations in
HIV infection by showing an effect of exercise on plasma
hsCRP, IL-6 and IL-18 also in patients undergoing moder-
ate intensity exercise. In addition, our findings seem to
disclose a beneficial effect of exercise on plasma D-dimer.
In contrast to the above markers, we did not observe
changes of sCD14, a microbial translocation marker and
independent predictor of mortality in chronic HIV infec-
tion [32]. Likewise, plasma levels of lipopolysaccharide
(LPS) were not reduced by 16 weeks of endurance or
strength interventions [33], suggesting no relevant effect
of exercise on microbial translocation mechanisms.
Of note, we observed a marked decrease of the frequency
of CD8+/CD38+/HLA-DR+ activated T-cells following ex-
ercise in both training groups. The effect of physical exer-
cise on T-cell activation is unknown, with only one study
showing no change in HLA-DR expression on CD3+ or
CD8+ T-cells in HIV-negative elderly following exercise
[34]. CD8+ T-cell activation is considered a less strong
predictor of mortality and non-AIDS defining events in
treated HIV infection than soluble immune activation
markers [35, 36]. However, it has been associated with
certain non-AIDS comorbidities, such as visceral fat ac-
cumulation and subclinical carotid artery disease [37, 38].
Our findings, though preliminary and obtained in a small
group of patients, suggest that decreased T-cell activation
might contribute to mediate exercise-induced health benefit.
The interpretation of the effect of different exercise
programs on inflammatory markers was limited by the
small sample size of training groups. However, reduc-
tions of hsCRP and CD8+/CD38+/HLA-DR+ cells were
observed in both training groups, likely reflecting high
sensitivity of these markers to exercise. Also, D-dimer
did not improve in the strength-walk group, and there
was in this group a non-significant increase of IL-6 con-
centrations. Similarly, a program of strength exercise
alone did not improve plasma hsCRP or IL-6 in a previ-
ous study of HIV-infected subjects [22], suggesting that
aerobic and resistance exercise might modulate inflam-
mation in different ways [4, 22].
More in general, two main mechanisms have been sug-
gested to mediate the effect of exercise on inflammation.
First, the reduction of fat mass following physical activity
may promote an anti-inflammatory environment via re-
duced infiltration of immune cells in the adipose tissue and
release of adipokines, including pro-inflammatory cyto-
kines [39]. In addition, contracting skeletal muscle secretes
molecules with immunomodulatory effects, including the
so-called myokines, most notably IL-6, which mediates
metabolic changes during exercise. While single bouts of
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exercise induce an increase of IL-6 and other cytokines,
regular exercise with repeated bouts may induce an
anti-inflammatory environment, with lower basal levels
of inflammatory markers over time [5]. Compared to
the general population, inflammation in HIV infection
may be caused or enhanced by specific conditions, includ-
ing persisting low-level HIV replication, chronic co-
infections, and ART-induced altered lipid and metabolic
profiles [28], suggesting that additional mechanisms may
mediate and perhaps enhance the effects of exercise on
inflammation.
From a clinical stand-point, exercise-induced improve-
ment of inflammatory markers may be relevant because
persistent low-level inflammation is associated with the
presence of chronic diseases, such as CVD, stroke, type-
2 diabetes and cancers [2] and increased mortality, both
in HIV-positive persons and in the general population
[2, 8, 9]. Among the studied inflammatory markers, only
hsCRP is currently used in clinical practice to assess the
risk of CVD and ischemic events in individuals without
manifest disease. Several other markers have the poten-
tial to guide and monitor treatment intervention decisions,
however their transferability into clinical practice will re-
quire efforts in terms of validation of biomarker assays and
intervention thresholds and to confirm changes of bio-
marker levels in the context of clinical trials.
This pilot study also showed that a 12-week exercise
program of walking was feasible and associated with ac-
ceptable discontinuation rate (28%) and adherence (67%).
In addition, none of the participants experienced physical
injuries or other medical problems directly related to exer-
cise. Although we did not define ‘a priori’ the feasibility of
the proposed intervention, the present study clarified a
number of issues defining feasibility, which include the
number of eligible participants, the methods and willing-
ness of clinicians to recruit participants; the practicality of
the intervention in the given setting and its acceptability
to the users, the discontinuation and adherence rates, the
availability of data needed and the time needed to collect
and analyse data [40].
According to a recent meta-analysis the overall with-
drawal rate from exercise interventions was of 24%, with
a widely variable range of 0 to 76% [1]. In our study the
most frequent reason for study drop-out was the inability
of participants to handle with family or work commit-
ments, which often reflects demotivation and is the major
reason for not exercising in the general population.
Adherence to the exercise intervention has been re-
ported in only a few studies, with rates of 61–100% [1].
However, criteria for defining adherence vary among
studies – e.g., the rate of patients attending at least a
given proportion of session rather the actual rate of
attended sessions, like in our study. We believe that, in
the present study, adherence was favoured by coach
supervision during all sessions [1] and, possibly, also by
training outdoor during spring-summer. Exercising in
natural environments is associated with greater positive
engagement compared with exercising indoors [41] and
also with greater exercise adherence [42]. However, it
seems likely, and also confirmed by our experience, that
the effect of outdoor training on adherence may vary
depending on weather conditions and thus on the sea-
son of the year and geographical area.
This study has some limitations. First, we did not in-
clude a non-exercise group as control for marker varia-
tions. However, there were no changes of medications,
including lipid-lowering drugs, in the weeks before or
during the training period, which may have affected study
outcomes beyond exercise. Second, assignment to either
training protocol was not randomized, but we purposely
left the choice of the training activity to participants - the
two groups trained in different places at different day
times - to favour participation. Although we did not rec-
ord systematically the reasons for training activity, overall
goals differed among participants, with most women wish-
ing to lose weight and most men to improve muscular fit-
ness. This resulted in an unbalanced women distribution
between training groups - indeed all the women opted for
the walk training program. However, no other relevant
differences were observed at baseline between training
groups. Also, the relatively small sample size of sub-
groups, and consequent low statistical power, did not
allow drawing firm conclusions on the efficacy of differ-
ent exercise programs or according to gender or other
variables. Finally, dietary intake was not restricted,
which might have influenced study outcomes.
Like most longitudinal studies assessing the effects of
exercise on different markers [3], this was a relatively
short-duration study. Therefore, it will be essential in
the future to assess the feasibility and the efficacy of
long-term, possibly self-managed, exercise approaches.
Conclusions
This pilot study suggests that brisk walking may improve
cholesterol profile and soluble and cell inflammatory
markers in sedentary patients with treated HIV infection
and metabolic problems. It provides potentially relevant
information for the design of larger controlled studies of
moderate physical exercise as treatment of HIV-related
chronic immune activation.
Additional files
Additional file 1: Table S1. Performance of participants during the
12 weeks of training in the walk group divided by gender. Values as
expressed as median (Q1-Q3). a. The median HRmean value was calculated
for each participant through all his/her walking sessions, to derive the
median HRmean value of all participants. HR, heart rate. (DOCX 38 kb)
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Additional file 2: Table S2. Physical fitness values by the 6 min Walking
Test (6MWT) at baseline (BL) and week-12 (W12) in the walk group divided
by gender. Values as expressed as median (Q1-Q3). W12 values were
compared to BL values by the Wilcoxon matched-pairs signed rank test.
a. At BL, women had higher %HRmean than men (p = 0.021, Mann–Whitney
test). HR, heart rate; Δ[La−], difference in lactate blood concentration
between before and after 6MWT; Δ RPE, difference in Rate of Perceived
Exertion between before and after 6MWT. (DOCX 48 kb)
Additional file 3: Table S3. 1-Repetition Maximum Test performance at
baseline (BL) and week-12 (W12). Values are expressed as median (Q1-Q3).
W12 values were compared to BL values by the Wilcoxon matched-
pairs signed rank test. HR, heart rate; Δ[La−], difference in lactate blood
concentration between before and after 6MWT; Δ RPE, difference in
Rate of Perceived Exertion between before and after 6MWT. (DOCX 39 kb)
Additional file 4: Table S4. Additional body composition and
laboratory values at baseline (BL) and week-12 (W12). Values are
expressed as median (Q1-Q3). W12 values were compared to BL values
by the Wilcoxon matched-pairs signed rank test. BMI, body mass index;
DEXA, Dual-energy X-ray absorptiometry; HOMA, Homeostasis Model
Assessment; VACS, Veterans Ageing Cohort Study (DOCX 100 kb)
Additional file 5: Table S5. Body composition and laboratory values at
baseline (BL) and week-12 (W12) in the walk group divided by gender.
Values as expressed as median (Q1-Q3). W12 values were compared to
BL values by the Wilcoxon matched-pairs signed rank test. a. At BL,
women had higher % fat in the arm (p = 0.015), leg (p = 0.034) and as
total (p = 0.017), lower haemoglobin (p = 0.002) and creatinine levels
(p = 0.008), and higher CD4 cell counts (p = 0.009) (Mann–Whitney
test). BMI, body mass index; DEXA, Dual-energy X-ray absorptiometry;
HOMA, Homeostasis Model Assessment; VACS, Veterans Ageing Cohort
Study (DOCX 94 kb)
Additional file 6: Table S6. Values of cholesterol at baseline (BL) and
week-12 (W12) in patients untreated with statins. Values are expressed as
median (Q1-Q3). W12 values were compared to BL values by the
Wilcoxon matched-pairs signed rank test. (DOCX 46 kb)
Additional file 7: Table S7. Values of inflammatory markers at baseline
(BL) and week-12 (W12) in the walk group divided by gender. Values as
expressed as median (Q1-Q3). W12 values were compared to BL values
by the Wilcoxon matched-pairs signed rank test. b. A subset of women
(n = 3) and men (n = 7) were tested for cell activation markers. HsCRP,
high sensitivity C-reactive protein; IL-6, interleukin-6; IL-8, interleukin-18;
sCD14, soluble CD14. (DOCX 51 kb)
Abbreviation
1RM: 1 repetition maximum; 6MWT: Six minutes walking test; AIDS: Acquired
immunodeficiency virus; BL: Baseline; BMC: Body mineral content; BMD: Bone
mineral density; BMI: Body mass index; cART: Combination antiretroviral
treatment; CD4+: Cluster of differentiation 4; CD8+: Cluster of differentiation
8; CVD: Cardiovascular diseases; DBP: Diastolic blood pressure; DEXA: Dual-energy
X-ray absorptiometry; FDAAA: Food and drug administration amendments act;
Hb1Ac: Glycated haemoglobin; HDL: High-density lipoprotein; HIV: Human
immunodeficiency virus; HOMA: Homeostatic model assessment; HR: Heart rate;
HRmax: Maximal heart rate; HRmean: Mean heart rate; hsCRP: High sensitivity
c-reactive protein; IL-18: Interleukin 18; IL-6: Interleukin 6; LDL: Low-density
lipoprotein; m: Men; NNRTI: Non nucleoside reverse transcriptase inhibitors;
NRTI: Nucleoside reverse transcriptase inhibitors; RPE: Rating of perceived
exertion; SBP: Systolic blood pressure; sCD14: Soluble CD14; VACS: Veteran
aging cohort study risk; VL: Viral load; w: Women; W12: Week 12;
Δ RPE: Difference in rate of perceived exertion between before and after
6MWT; Δ[La−]: Difference in lactate blood concentration between before
and after 6MWT
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